Success Story: NIW Approved for a Nanobiotechnology Researcher from Iran

Client’s Testimonial:

 

“Thank you for your assistance throughout my EB-2 NIW process.”

 


 

In September, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Nanobiotechnology (Approval Notice).

 


 

General Field: Nanobiotechnology

 

Country of Origin: Iran

 

Approval Notice Date: September, 2026

 

Processing Time: More than 25 months (Premium Processing Requested)

 


 

Case Summary:

 

This case presented an important point about the National Interest Waiver: a client did not need to be employed at the time of filing for the client's professional trajectory and future plans to support a compelling petition. Although the client had no employment at the time of case filing, the client brought substantial prior experience in nanobiotechnology and a defined plan to continue research in regenerative medicine. North America Immigration Law Group (Chen Immigration Law Associates) presented that broader record to demonstrate the client's capacity to continue contributing to the field.

 

The client’s advanced academic background established a robust foundation for the proposed endeavor. Over the course of their research career, the client developed specialized expertise in engineering advanced biological materials and novel therapeutic systems. The proposed work builds seamlessly on this track record, focusing on engineering next-generation materials and technologies to drive broader advancements in clinical therapeutics and physiological recovery.

 

The petition demonstrated an established record of scholarly activity. The client had authored more than 5 peer-reviewed journal articles. The client's published work had accumulated over 200 citations, and the client had completed more than 20 peer reviews for journals and conferences. These credentials helped show both sustained participation in the field and recognition of her expertise by the broader research community.

 

The petition strategically highlighted the broader scientific adoption of the client's published research. Independent investigators had actively relied on these foundational findings to drive subsequent studies. By documenting this widespread use, the filing demonstrated that the work's impact extended well beyond the client's own laboratory. This established track record proved that the proposed continuation of the research was backed by a demonstrated history of advancing critical, related scientific disciplines.

 

The petition further explained the broader significance of continuing this work. It also connected the client’s expertise with U.S. interests in biotechnology, advanced materials, and advanced manufacturing. After a lengthy adjudication period, the client submitted a premium processing upgrade in July, 2026, and the NIW petition was ultimately approved in September, 2026, concluding a 25-month process. We wish the client continued success as the client moves forward with this work in nanobiotechnology and regenerative medicine.